A provider briefing on Aller-Cort (Triamcinolone nasal spray) availability in 2026 — shortage status, prescribing implications, and patient access tools.
If your patients are reporting difficulty finding Kirkland Signature Aller-Cort, this briefing gives you the current picture on availability, prescribing considerations, and tools you can recommend to help patients access their allergy medications.
Bottom line up front: Triamcinolone Acetonide nasal spray is not in a formal FDA shortage. Aller-Cort, a Costco-exclusive store brand, experiences periodic stock-outs driven by seasonal demand and limited distribution — not supply chain failure. The active pharmaceutical ingredient is widely available under multiple OTC and prescription formulations.
As of March 2026, Triamcinolone Acetonide nasal spray is not listed on the FDA Drug Shortage Database or the ASHP drug shortage resource. Production volumes across all manufacturers remain at normal levels.
Patient complaints about difficulty finding "Aller-Cort" specifically are most common during:
These reports are specific to the Kirkland Signature branded product sold exclusively at Costco warehouses. Equivalent Triamcinolone Acetonide nasal sprays remain readily available at chain and independent pharmacies nationwide.
Triamcinolone Acetonide nasal spray has been available over the counter since 2014 (as Nasacort Allergy 24HR). Key considerations for prescribers:
Long-term use of intranasal corticosteroids may slow growth velocity in children. The product labeling recommends discussing with parents/guardians if a child needs the medication for more than 2 months per year. Monitor growth parameters at routine well-child visits for children on chronic intranasal steroids.
The intranasal corticosteroid category remains one of the most well-supplied drug classes in the U.S. Multiple manufacturers and formulations ensure broad availability:
Understanding the cost landscape helps when counseling patients:
For patients facing cost barriers, HSA/FSA funds can be used for OTC nasal steroids. Some state Medicaid and Medicare Advantage plans include OTC benefits that cover these products.
Medfinder offers a provider-facing tool that helps you and your staff check medication availability at pharmacies near your patients. This can be especially useful when directing patients to pharmacies that have their medication in stock.
You can direct patients to these resources on medfinder.com:
While intranasal corticosteroids have minimal systemic absorption and few clinically significant drug interactions, be aware of additive corticosteroid effects in patients on:
For a full interaction reference, see Aller-Cort drug interactions.
The intranasal corticosteroid market is stable with no anticipated supply disruptions for 2026. Key trends to watch:
Aller-Cort availability issues are a distribution and demand problem, not a supply shortage. Patients who report difficulty finding their allergy spray can be confidently redirected to equivalent OTC products at any pharmacy. For those who benefit from prescription coverage, Mometasone nasal spray or prescription Triamcinolone remain effective and accessible options.
Explore Medfinder for Providers to add real-time medication availability checks to your practice workflow. For the companion patient-facing update, see Aller-Cort shortage update: what patients need to know in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
